Compare XPON & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPON | MBIO |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 4.1M |
| IPO Year | 2022 | 2023 |
| Metric | XPON | MBIO |
|---|---|---|
| Price | $2.50 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.8K | ★ 36.8K |
| Earning Date | 11-16-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 94.63 | ★ 98.99 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,651,870.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $405.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 71.59 | N/A |
| 52 Week Low | $0.26 | $0.35 |
| 52 Week High | $11.79 | $1.44 |
| Indicator | XPON | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 29.06 | 45.60 |
| Support Level | $0.51 | $0.35 |
| Resistance Level | $3.82 | $0.43 |
| Average True Range (ATR) | 0.34 | 0.03 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 14.21 | 64.93 |
Expion Energy Inc is engaged in premium lithium iron phosphate (LiFePO4) batteries and accessories for recreational vehicles, marine applications, Light EV and industrial applications. The company's lithium-ion batteries feature half the weight of standard lead-acid batteries while delivering three times the power and ten times the number of charging cycles. The company's batteries also feature construction and reliability compared to other lithium-ion batteries on the market due to their superior design and quality materials.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.